On September 29, 2020 Neuropore Therapies, Inc. reported that it has licensed two mechanistically distinct classes of potent, selective and brain penetrating modulators of mTOR–regulated autophagy to Global Cancer Technology (Press release, Neuropore Therapies, SEP 29, 2020, View Source [SID1234567766]). This portfolio of small molecule autophagy modulators, targeting PI3K and VPS34, was discovered by Neuropore Therapies and characterized using its comprehensive platform of autophagy and lysosomal biogenesis cellular assays. Neuropore Therapies will continue to investigate the utility of autophagy modulators for the treatment of neurodegenerative disorders while Global Cancer Technology will pursue the use of these PI3K and VPS34 inhibitors for the treatment of cancers and other life-threatening diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Doug Bonhaus, CEO of Neuropore Therapies, commented, "Modulators of autophagy have therapeutic potential in a wide range of diseases including cancers, metabolic and neurodegenerative disorders. While Neuropore Therapies continues to explore the therapeutic potential of autophagy modulators for neurodegenerative disorders, we are very pleased to see the therapeutic potential of these PI3K and VPS34 targeted compounds pursued for additional indications."

On September 29, 2020 Polyphor AG (SIX: POLN) reported the closing of the previously announced exclusive licensing agreement with Fosun Pharma for balixafortide in China (Press release, Polyphor, SEP 29, 2020, View Source [SID1234567844]). As a result of closing the transaction, Polyphor received the agreed upfront payment of $15 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Polyphor and Fosun Pharma will develop and commercialize balixafortide for the Chinese market with an initial focus on metastatic breast cancer. China is projected to be the second largest market globally for breast cancer treatments. Additional cancer indications and combination therapies will be evaluated jointly by the companies. Polyphor retains all rights to balixafortide outside of China.

In addition to the upfront payment, Polyphor is eligible for additional development milestone payments of up to $19 million, sales milestone payments of up to $148 million plus up to mid-teen royalties on net sales achieved in the territory.

Fosun Pharmaceutical AG is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd ("Fosun Pharma", stock code: 600196.SH; 02196.HK), a leading healthcare company in China. It is listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange.

On September 29, 2020 Penumbra, Inc. (NYSE: PEN) reported that it will host a conference call to discuss financial results for the third quarter 2020 after market close on Wednesday, October 28, 2020 at 4:30 PM Eastern Time (Press release, Penumbra, SEP 29, 2020, View Source [SID1234567767]). Penumbra is hosting its call in advance of Election Day 2020, which will be a paid company holiday for Penumbra’s U.S. employees to support their right to participate in our democracy. A press release with third quarter 2020 financial results will be issued after market close on October 28, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast & Conference Call Information
The conference call can be accessed live over the phone by dialing (833) 350-1434 for domestic and international callers (conference id: 3538526), or the webcast can be accessed on the "Events" section under the "Investors" tab of the Company’s website at: www.penumbrainc.com. The webcast will be available on the Company’s website for at least two weeks following the completion of the call.

On September 29, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that the company’s management will present at the Jefferies Virtual Cell Therapy Conference on Tuesday, October 6 at 8:00 a.m. Eastern Time (Press release, Affimed, SEP 29, 2020, View Source [SID1234567738]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed under the "Investors" section of Affimed’s website at View Source and will be available for 30 days following the event.

On September 29, 2020 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, reported that it has commenced an underwritten public offering of its shares of common stock (Press release, Cardiff Oncology, SEP 29, 2020, View Source [SID1234567768]). In addition, Cardiff Oncology expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its shares of common stock sold in the public offering. All of the shares are being offered by Cardiff Oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cardiff Oncology intends to use the net proceeds from this offering for clinical development of its product candidate, onvansertib, working capital and for other general corporate purposes.

Cowen and Piper Sandler & Co. are acting as joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 which has been filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on July 1, 2019. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement relating to the offering will be filed with the SEC. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at [email protected] and Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.